Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170025/S023

Aptima HBV Quant Assay Kit, 100T; Aptima HBV Quant Calibrator Kit; Aptima HBV Quant Controls Kit; Aptima HBV Quant Targe

Hologic, Inc. · Decision date Oct 7, 2025

FDA DECISIONP170025/S023

What did the FDA decide?

FDA records P170025/S023 as a supplement to PMA P170025, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 7, 2025.

FDA approval order statement

to adjust raw material test method
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Microbiology
Decision date
Oct 7, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P170025/S023
Regulatory pathway
PMA supplement
Applicant
Hologic, Inc.
Product code
MKT
Decision code
OK30
Decision date
Oct 7, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Hepatitis Viral B DNA Detection.

Applicant
Hologic, Inc.
Product code
MKT
FDA device class
2

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P170025/S023 received

    Application receipt date recorded by FDA.

  2. P170025/S023 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P170025. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code MKT

Product / regulatory recordCompanyPathwayDecision dateSource
cobas HBVP150014/S056
Roche Molecular Systems, Inc.PMA supplementOct 17, 2025FDA
Alinity m HBVP200013/S027
Abbott Molecular, Inc.PMA supplementOct 17, 2025FDA
Alinity m HBVP200013/S026
Abbott Molecular, Inc.PMA supplementSep 24, 2025FDA
cobas HBVP150014/S058
Roche Molecular Systems, Inc.PMA supplementSep 19, 2025FDA
cobas HBVP150014/S057
Roche Molecular Systems, Inc.PMA supplementAug 7, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Hologic, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
10210 Genetic Center Dr., San Diego, CA, 92121

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records